Contract analysis

I. Executive Summary Calderwood & Harkness LLP has been engaged by Penterra Pharmaceuticals Corp. ("Penterra" or "PPC"), a Delaware corporation publicly traded on the Nasdaq Stock Market (ticker: PNTR), headquartered at 400 Pharma Drive, Suite 800, Princeton, New Jersey 08540, in connection with the potential out-licensing of its proprietary small-molecule compound PPC-4187 (proposed International Nonproprietary Name

II. Background A. The Compound — PPC-4187 PPC-4187, for which the proposed International Nonproprietary Name (INN) is Penteracitinib, is a selective Janus kinase 1 (JAK1) inhibitor designed for oral administration. PPC-4187 was discovered and developed internally by Penterra's medicinal chemistry and drug discovery teams at the company's Princeton, New Jersey research facility. The compound is formulated as a once-da

III. Patent Portfolio Overview The PPC-4187 patent portfolio comprises a total of seven (7) patent families, each directed to a distinct aspect of the PPC-4187 compound, formulation, or methods of use. Collectively, these families provide layered intellectual property protection that covers the PPC-4187 molecule itself, its preferred crystalline form, its therapeutic applications, the specific pharmaceutical formulat

IV. Patent Portfolio — Jurisdiction-by-Jurisdiction Summary for Contemplated Territory This section provides a jurisdiction-by-jurisdiction summary of the PPC-4187 patent portfolio status in each country or territory encompassed by the contemplated Territory, together with key regulatory and enforcement considerations relevant to the out-license transaction. A. People's Republic of China (including Hong Kong SAR and

V. Trademark Portfolio — PENTECLAR Penterra has adopted PENTECLAR as the proposed trade name under which PPC-4187 (Penteracitinib) would be marketed commercially. The PENTECLAR trademark portfolio includes the following registrations and applications: The specific registration or application numbers, filing dates, and current status of the trademark filings in Hong Kong, China, Japan, South Korea, and Australia will

VI. Know-How and Data Assets In addition to the patent and trademark portfolio, Penterra possesses a substantial body of proprietary know-how, trade secrets, and data assets relating to PPC-4187 that will constitute a critical component of the license grant and technology transfer in the contemplated out-license transaction. These assets include, without limitation, the following:

1. Proprietary Manufacturing Process Documentation: Complete documentation of the validated manufacturing process for PPC-4187 active pharmaceutical ingredient and finished dosage form, including batch manufacturing records, process validation protocols and reports, process flow diagrams, equipment specifications, and in-process testing procedures. This documentation reflects the manufacturing process developed by Pe

2. Analytical Methods and Specifications: Validated analytical methods for identity, purity, potency, and dissolution testing of PPC-4187 API and finished dosage form, including HPLC methods, spectroscopic methods, and physical characterization methods. Specifications for release testing and stability testing are included.

3. Pre-Clinical Data Packages: Comprehensive pre-clinical data, including pharmacology studies (in vitro and in vivo efficacy studies demonstrating JAK1 selectivity and anti-inflammatory activity), toxicology studies (single-dose and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity), and ADME (absorption, distribution, metabolism, and excretion) studies.

4. Clinical Data Packages: Complete clinical data packages from Penterra-sponsored clinical trials, including the full Study PPC-4187-201 database (Phase IIb, 420 patients, randomized double-blind placebo-controlled, EASI-75 at Week 16 primary endpoint). The clinical data package also includes data from the Phase I study (PPC-4187-101), including pharmacokinetic, safety, and tolerability data from healthy volunteers

5. Stability Data: Long-term, intermediate, and accelerated stability data for PPC-4187 API and finished dosage form, conducted in accordance with ICH Q1A(R2) guidelines. Stability data supporting the proposed shelf life and storage conditions for the commercial product.

6. CMC Documentation: Complete Chemistry, Manufacturing, and Controls documentation, including Module 3 of the Common Technical Document ("CTD"), as prepared for regulatory submissions in the United States and European Union. This documentation includes drug substance characterization, drug product formulation development, manufacturing process descriptions, container closure system information, and reference standar

VII. Preliminary Observations on Licensing Suitability A. Strengths Based on our preliminary review, the PPC-4187 intellectual property portfolio exhibits several significant strengths that support its suitability for an exclusive territorial out-license:

1. Core Composition-of-Matter Patents Granted in All Major APAC Markets. The grant of composition-of-matter patents in the United States (U.S. Patent No. 11,234,567), China (CN Patent No. ZL 2020 1 0456789.0), Japan (JP Patent No. 7,012,345), South Korea (KR Patent No. 10-2345678), and Australia (AU Patent No. 2020234567) provides the broadest and most commercially valuable form of patent protection in all four major

2. Crystalline Form Patent Extends Protection Beyond Composition-of-Matter Expiry. The granted U.S. crystalline form patent (U.S. Patent No. 11,345,678) extends protection to November 3, 2038, approximately fourteen months beyond the composition-of-matter expiry. If corresponding crystalline form patents are granted in the Territory jurisdictions, this extended protection could provide an important additional period

3. Multiple Patent Families Create Layered Protection. The portfolio's seven (7) patent families — covering composition of matter, crystalline form, methods of use, pharmaceutical formulation, manufacturing process, combination therapy, and dosage regimen — create a comprehensive, multi-layered defensive position. This layered approach is consistent with pharmaceutical industry best practices for lifecycle management

4. Strong Clinical Data Supporting Commercial Value. The Phase IIb clinical data from Study PPC-4187-201 (420 patients; statistically significant improvement vs. placebo with p<0.001 at the EASI-75 primary endpoint at Week 16) provides a strong evidentiary foundation for the commercial potential of PPC-4187. Strong clinical data enhances the value of the intellectual property portfolio by confirming that the protecte

5. Validated Manufacturing Process with Established CMO. The validation of the PPC-4187 manufacturing process at Alkerra Manufacturing Inc. provides a clear and well-documented pathway for technology transfer to the licensee or the licensee's designated contract manufacturer in the Territory. A validated manufacturing process reduces the development risk associated with the out-license and facilitates the regulatory

6. Trademark PENTECLAR Registered or Filed in Key Territory Jurisdictions. The existence of trademark registrations or applications for PENTECLAR in the United States, Hong Kong, China, Japan, South Korea, and Australia provides a brand identity that can be licensed to the Territory partner, enhancing the commercial value of the out-license package. B. Areas Requiring Further Diligence Notwithstanding the strengths i

1. Freedom-to-Operate Analysis. A comprehensive freedom-to-operate ("FTO") analysis covering all Territory jurisdictions is essential to confirm that the manufacture, use, sale, offer for sale, and importation of PPC-4187 products in the Territory would not infringe any valid and enforceable third-party patent rights. Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford) has been identified to provide this opin

2. Third-Party Patent Landscape. The JAK inhibitor therapeutic class is highly competitive, with multiple pharmaceutical companies developing JAK1, JAK1/2, and pan-JAK inhibitors for dermatological and other indications. Key competitors in the JAK inhibitor space include, among others, the approved products upadacitinib (Penrose & Co.) and abrocitinib (Ashbury Industries), as well as multiple compounds in clinical de

3. Prosecution Status of Pending Applications in ASEAN. The status of pending patent applications in Singapore and the six additional ASEAN jurisdictions is currently unconfirmed. Prosecution timelines and grant prospects in these jurisdictions may be uncertain, and there is a risk that some applications may not result in granted patents. The comprehensive diligence report should include a jurisdiction-by-jurisdictio

4. Patent Term Extension Potential. The potential for patent term extensions in Japan, Australia, and other Territory jurisdictions upon regulatory approval should be analyzed in detail. Patent term extensions can significantly enhance the effective exclusivity period and therefore the commercial value of the licensed intellectual property. The PTE analysis should account for the anticipated regulatory submission and

5. Enforceability of Methods-of-Use and Dosage Regimen Claims. As discussed in Sections III.C and III.G above, the enforceability of methods-of-use and dosage regimen claims varies by jurisdiction, with particular uncertainty in China and certain ASEAN markets. A detailed analysis of the enforceability of these claims in each Territory jurisdiction is necessary to accurately assess the portfolio's protective scope.

6. Trademark Clearance in Additional Jurisdictions. Trademark clearance searches for PENTECLAR have not yet been completed in all Territory jurisdictions, particularly in the ASEAN countries, Taiwan, and New Zealand. These searches should be completed to confirm that the PENTECLAR mark is available for use and registration throughout the Territory.

7. Existing Encumbrances and Prior Licenses. Penterra should confirm whether any existing encumbrances, liens, security interests, or prior license agreements affect any portion of the PPC-4187 intellectual property portfolio. The existence of any such encumbrances could limit Penterra's ability to grant an exclusive license in the Territory and must be identified and addressed prior to execution of the definitive li

1. Licensed Patents Schedule. The license agreement should include a comprehensive schedule listing all patents and patent applications in all seven (7) families, organized by jurisdiction, with detail including patent numbers, application numbers, filing dates, grant dates, expiration dates, and current prosecution status. The schedule should include a mechanism for regular updating to reflect new grants, new filing

2. Licensed Know-How Definition. The definition of "Licensed Know-How" should be drafted comprehensively to cover all proprietary information necessary for the development, regulatory approval, manufacture, and commercialization of PPC-4187 in the Territory, including clinical data, manufacturing process documentation, analytical methods, stability data, CMC documentation, and any future data generated by Penterra.

3. Patent Prosecution and Maintenance Obligations. The license agreement should allocate responsibility for patent prosecution, maintenance (including payment of annuities and renewal fees), and defense between Penterra (as licensor) and the licensee. We recommend the establishment of a Joint Patent Committee with representatives from both parties to coordinate prosecution and maintenance activities, share informatio

4. IP Infringement Indemnity. The license agreement should address Penterra's indemnification obligations with respect to intellectual property infringement claims arising from the licensee's exercise of the licensed rights. The scope of this indemnity, including any limitations, caps, baskets, and carve-outs, will be a significant point of negotiation. Standard provisions would typically include indemnification for

5. Technology Transfer Timeline. The technology transfer timeline should be aligned with the anticipated regulatory submission schedule in the Territory jurisdictions. A phased technology transfer approach may be appropriate, with initial transfer of regulatory data and clinical information followed by transfer of manufacturing process know-how upon selection of the licensee's designated manufacturing site.

6. Sublicensing Provisions. If the licensee is permitted to sublicense any portion of the licensed rights (e.g., to local distributors or manufacturing partners in specific Territory jurisdictions), the sublicense provisions should require flow-down of all material IP protections, including confidentiality obligations, use restrictions, quality control requirements, and reporting obligations. Penterra should retain t

VIII. Identified IP Risks (Preliminary) Based on our preliminary review, we have identified the following intellectual property risks that should be further evaluated during the comprehensive diligence phase: Third-Party Patent Assertion Risk. The JAK inhibitor therapeutic class is a highly active area of pharmaceutical research and development, with numerous companies holding patents on JAK inhibitor compounds, form